retatrutide peptide fda approval Update: Eli Lilly's Game Changer Retatrutide triples weight loss in

As you can see from the side-by-side Figure below, the new trial (at left) replicates the previous one for symptomatic benefit and reduced physical limitations (Y-axis, corresponding to the Kansas City score) with the primary endpoint findings remarkably similar

The medication is a triple-agonist drug, meaning it mimics three appetite hormones: GLP-1, GIP, and glucagon

[5][6] For these patients, a microdose may be enough to restore metabolic balance without the need for aggressive appetite suppression

How to Adjust Your Training When Taking a GLP-1 (Without Quitting Altogether) Here are some tricks to make training more accessible even when the body is going through changes associated with GLP-1s

Alterations of sucrose preference after Roux-en-Y gastric bypass